ArticleTrials2025

A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS).

Marlies Ostermann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.